Post-bariatric hypoglycemia (PBH) has emerged as a significant and increasingly recognized long-term metabolic complication following bariatric surgery, particularly Roux-en-Y gastric bypass. This systematic review, synthesizing evidence from 30 studies encompassing over 3,250 patients, reveals a widely variable incidence ranging from 0.2% to over 30%, a disparity largely attributable to differences in diagnostic methods, surgical types, and follow-up durations. The condition is not a uniform entity but is influenced by a constellation of risk factors, most consistently including the type of procedure (with RYGB carrying the highest risk), female sex, rapid and significant weight loss, an exaggerated postprandial incretin response, and a lower preoperative BMI. The management of PBH necessitates a structured, stepwise approach. The foundational strategy is dietary modification, focusing on low-glycemic index carbohydrates and small, frequent meals to mitigate rapid glucose shifts. When lifestyle interventions are insufficient, a range of pharmacological options can be employed, including acarbose to delay carbohydrate absorption, and diazoxide or verapamil to modulate insulin secretion. In severe, refractory cases, surgical revision, while rare, may be considered. The integration of continuous glucose monitoring (CGM) has proven invaluable for both diagnosis and patient education, often uncovering asymptomatic hypoglycemic episodes. Ultimately, PBH is a multifactorial and likely underdiagnosed condition that underscores the complex metabolic alterations after bariatric surgery. Its management demands individualized, multidisciplinary care, and the field would greatly benefit from standardized diagnostic criteria and more robust long-term studies to optimize patient outcomes and clarify its potential implications for broader cardiometabolic health.